UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies

Immunotherapy, 2014-05, Vol.6 (5), p.553-567

Wasserman, Richard L

2014

Volltextzugriff (PDF)

Information needs of patients considering oral immunotherapy for food allergy

Clinical and experimental allergy, 2022-12, Vol.52 (12), p.1391-1402

2022

Volltextzugriff (PDF)

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks

Journal of allergy and clinical immunology, 2009-10, Vol.124 (4), p.801-808

2009

Volltextzugriff (PDF)

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

Journal of allergy and clinical immunology, 2012-10, Vol.130 (4), p.951-957.e11

2012

Volltextzugriff (PDF)

Microbiological, Physicochemical, and Immunological Analysis of a Commercial Cashew Nut-Based Yogurt

International journal of molecular sciences, 2020-11, Vol.21 (21), p.8267

2020

Volltextzugriff (PDF)

Traveling with primary immunodeficiency

Annals of allergy, asthma, & immunology, 2023-04, Vol.130 (4), p.422-424.e4

Wasserman, Richard L.

2023

Volltextzugriff (PDF)

Immunoglobulin replacement therapy stewardship in modern times

Annals of allergy, asthma, & immunology, 2022-11, Vol.129 (5), p.546-547

Wasserman, Richard L.

2022

Volltextzugriff (PDF)

Reply to high cost of immunoglobulin replacement therapy: Causes and implications

Annals of allergy, asthma, & immunology, 2023-02, Vol.130 (2), p.258-258

Wasserman, Richard L.

2023

Volltextzugriff (PDF)

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

Frontiers in immunology, 2021-07, Vol.12, p.707463-707463

2021

Volltextzugriff (PDF)

Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases

Immunotherapy, 2017-09, Vol.9 (12), p.1035-1050

Wasserman, Richard L

2017

Volltextzugriff (PDF)

Hizentra for the treatment of primary immunodeficiency

Expert review of clinical immunology, 2014-10, Vol.10 (10), p.1293-1307

Wasserman, Richard L

2014

Volltextzugriff (PDF)

Personalized Therapy: Immunoglobulin Replacement for Antibody Deficiency

Immunology and allergy clinics of North America, 2019-02, Vol.39 (1), p.95-111

Wasserman, Richard L

2019

Volltextzugriff (PDF)

Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment

Allergy and asthma proceedings, 2021-11, Vol.42 (6), p.489-494

Wasserman, Richard L

2021

Volltextzugriff (PDF)

Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again

Journal of clinical immunology, 2012-12, Vol.32 (6), p.1153-1164

Wasserman, Richard L.

2012

Volltextzugriff (PDF)

The Nuts and Bolts of Immunoglobulin Treatment for Antibody Deficiency

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2016-11, Vol.4 (6), p.1076-1081.e3

Wasserman, Richard L., MD, PhD

2016

Volltextzugriff (PDF)

Common variable immunodeficiency and respiratory complications: take-home messages for the clinician

Annals of allergy, asthma, & immunology, 2020-05, Vol.124 (5), p.414-415

Wasserman, Richard L.

2020

Volltextzugriff (PDF)

Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study

Advances in therapy, 2020-04, Vol.37 (4), p.1536-1549

Wasserman, Richard L.

2020

Volltextzugriff (PDF)

Captaining the PIDD ship

Annals of allergy, asthma, & immunology, 2019-11, Vol.123 (5), p.419-419

Wasserman, Richard L.

2019

Volltextzugriff (PDF)

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

Clinical immunology (Orlando, Fla.), 2014-02, Vol.150 (2), p.161-169

2014

Volltextzugriff (PDF)

Towards an FDA-cleared basophil activation test

Frontiers in allergy, 2023-01, Vol.3, p.1009437-1009437

2023

Volltextzugriff (PDF)

Oral Immunotherapy for Peanut Allergy: Multipractice Experience With Epinephrine-treated Reactions

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2014, Vol.2 (1), p.91-96.e2

2014

Volltextzugriff (PDF)

Eosinophilic Esophagitis Like Oral Immunotherapy Related Syndrome (ELORS)

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB134-AB134

2017

Volltextzugriff (PDF)

Food Oral Immunotherapy (FOIT) Failures: Who and Why

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB134-AB134

2017

Volltextzugriff (PDF)

Sustained Unresponsiveness Following Food Oral Immunotherapy (FOIT)

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB132-AB132

2017

Volltextzugriff (PDF)

Balancing the risks and burdens of food allergen avoidance

Annals of allergy, asthma, & immunology, 2018-03, Vol.120 (3), p.229-230

Wasserman, Richard L.

2018

Volltextzugriff (PDF)

1 – 25 von 405

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(358)
Mit Volltextzugriff
(304)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(403)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies

Information needs of patients considering oral immunotherapy for food allergy

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

Microbiological, Physicochemical, and Immunological Analysis of a Commercial Cashew Nut-Based Yogurt

Traveling with primary immunodeficiency

Immunoglobulin replacement therapy stewardship in modern times

Reply to high cost of immunoglobulin replacement therapy: Causes and implications

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases

Hizentra for the treatment of primary immunodeficiency

Personalized Therapy: Immunoglobulin Replacement for Antibody Deficiency

Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment

Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again

The Nuts and Bolts of Immunoglobulin Treatment for Antibody Deficiency

Common variable immunodeficiency and respiratory complications: take-home messages for the clinician

Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study

Captaining the PIDD ship

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

Towards an FDA-cleared basophil activation test

Oral Immunotherapy for Peanut Allergy: Multipractice Experience With Epinephrine-treated Reactions

Eosinophilic Esophagitis Like Oral Immunotherapy Related Syndrome (ELORS)

Food Oral Immunotherapy (FOIT) Failures: Who and Why

Sustained Unresponsiveness Following Food Oral Immunotherapy (FOIT)

Balancing the risks and burdens of food allergen avoidance

Suchergebnisse filtern